Citius PharmaceuticalsCTXR -2.02%22 PB Ratio is 0.21 as of Jul. 08, 2026, which is 9% below its 10-year median of 0.23. GuruFocus rates CTXR with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,225 Biotechnology companies, Citius Pharmaceuticals ranks better than 98.2% on this metric.
Citius Pharmaceuticals Inc stock PB Ratio (=0.21) is close to 1-year low of 0.2.
The historical rank and industry rank for Citius Pharmaceuticals's PB Ratio or its related term are showing as below:
CTXR'
s PB Ratio Range Over the Past 10 Years
Min: 0.2 Med: 0.23 Max: 0.31
Current: 0.21
During the past 13 years, Citius Pharmaceuticals's highest PB Ratio was 0.31. The lowest was 0.20. And the median was 0.23.
CTXR's PB Ratio is ranked better than 98.2% of 1225
companies
in the Biotechnology industry
Industry Median: 2.92
vs CTXR: 0.21
During the past 12 months, Citius Pharmaceuticals's average Book Value Per Share Growth Rate was -60.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -40.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -24.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Citius Pharmaceuticals was -1.90% per year. The lowest was -126.30% per year. And the median was -35.10% per year.
Back to Basics: PB Ratio
Citius Pharmaceuticals (NAS:CTXR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Citius Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Citius Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Citius Pharmaceuticals (CTXR) has a PB Ratio of 0.21 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Citius Pharmaceuticals and its competitors. This is near median its historical median of 0.23. Over the past decade, Citius Pharmaceuticals' PB Ratio has ranged from 0.20 to 0.31. According to the industry distribution chart, Citius Pharmaceuticals ranks #22 out of 1225 companies in the Biotechnology industry, placing it in the top 1.8%.
Is Citius Pharmaceuticals' PB Ratio too high?
Citius Pharmaceuticals' current PB Ratio of 0.21 is near median its 10-year median of 0.23. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 0.31. The Biotechnology industry median PB Ratio is 2.92. Citius Pharmaceuticals' value of 0.21 is 92.8% below this industry median. Based on the distribution chart, Citius Pharmaceuticals ranks #22 out of 1225 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Citius Pharmaceuticals has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Citius Pharmaceuticals' PB Ratio compare to BIVI and CYCN?
According to the Biotechnology industry distribution chart, Citius Pharmaceuticals ranks #22 out of 1225 companies for PB Ratio. This places Citius Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.92. Citius Pharmaceuticals' value of 0.21 is 92.8% below this benchmark. Historically, Citius Pharmaceuticals' own PB Ratio has ranged from 0.20 to 0.31 over the past decade. While the company's 10-year median is 0.23 vs. the industry median of 2.92, Citius Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Pharmaceuticals's current PB Ratio of 0.21 is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Citius Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Pharmaceuticals's current PB Ratio is 0.21, which is near median its own 10-year median of 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Pharmaceuticals stock overvalued right now?
Citius Pharmaceuticals (CTXR) has a current PB Ratio of 0.21. The current PB Ratio is 0.21, which is near median its 10-year median of 0.23 and 92.8% below the Biotechnology industry median of 2.92. Citius Pharmaceuticals' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Citius Pharmaceuticals (CTXR), the current PB Ratio is 0.21 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
22GF Score
Get the complete analysis for CTXR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTXR has been successfully added to your 
